RNA Silencing of Checkpoint Regulators Sensitizes p53 -Defective Prostate Cancer Cells to Chemotherapy while Sparing Normal Cells
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
p53 is frequently mutated in patients with prostate cancer, especially in those with advanced disease. Therefore, the selective elimination of p53 mutant cells will likely have an impact in the treatment of prostate cancer. Because p53 has important roles in cell cycle checkpoints, it has been anticipated that modulation of checkpoint pathways should sensitize p53-defective cells to chemotherapy while sparing normal cells. To test this idea, we knocked down ataxia telangiectasia mutated (ATM) gene by RNA interference in prostate cancer cell lines and in normal human diploid fibroblasts IMR90. ATM knockdown in p53-defective PC3 prostate cancer cells accelerated their cell cycle transition, increased both E2F activity and proliferating cell nuclear antigen expression, and compromised cell cycle checkpoints, which are normally induced by DNA damage. Consequently, PC3 cells were sensitized to the killing effects of the DNA-damaging drug doxorubicin. Combining ATM knockdown with the Chk1 inhibitor UCN-01 further increased doxorubicin sensitivity in these cells. In contrast, the same strategy did not sensitize either IMR90 or LNCaP prostate cancer cells, both of which have normal p53. However, IMR90 and LNCaP cells became more sensitive to doxorubicin or doxorubicin plus UCN-01 when both p53 and ATM functions were suppressed. In addition, knockdown of the G2 checkpoint regulators ATR and Chk1 also sensitized PC3 cells to doxorubicin and increased the expression of the E2F target gene PCNA. Together, our data support the concept of selective elimination of p53 mutant cells by combining DNA damage with checkpoint inhibitors and suggest a novel mechanistic insight into how such treatment may selectively kill tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“(27, 28 ). Two shRNAs, each against human ATM, ATR, and Chk1 sequences (GenBank accession nos.”
BackgroundATM and related protein kinases: safeguarding genome integrity
Shiloh, Y. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1011 · Cited by 2,577 · cited 3×
“sensing DNA damage and activating p53-dependent cell death (22).”
BackgroundMethodLiu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes & Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625 · cited 1×
“The G2 checkpoint is controlled by the kinases ATM and ATR that receive DNA-damage signals activating downstream effectors such as the checkpoint kinases Chk1 and Chk2 (41, 49 , 50).”
BackgroundSeparate domains of p21 involved in the inhibition of Cdk kinase and PCNA
Chen, J., Jackson, P. K., Kirschner, M. W., & Dutta, A. (1995) · Nature · doi:10.1038/374386a0 · Cited by 548 · cited 1×
“For example, p21 is a major PCNA inhibitor (42); thus, cells disabled for both p53 and the ATM/ATR checkpoint pathways may have a synergistic increase in PCNA activity.”
BackgroundPML is induced by oncogenic ras and promotes premature senescence
Ferbeyre, G., de Stanchina, E., Querido, E., Baptiste, N., Prives, C., & Lowe, S. W. (2000) · Genes & Development · doi:10.1101/gad.14.16.2015 · Cited by 536 · cited 1×
“Retroviral infections were done as described (27).”
Self-citation
Cited by
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276
An E2F/miR-20a Autoregulatory Feedback Loop
Sylvestre, Y., De Guire, V., Querido, E., Mukhopadhyay, U. K., Bourdeau, V., Major, F., Ferbeyre, G., & Chartrand, P. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608939200 · Cited by 610
Self-citationThe DNA damage signaling pathway is a critical mediator of oncogene-induced senescence
Mallette, F. A., Gaumont-Leclerc, M.-F., & Ferbeyre, G. (2007) · Genes & Development · doi:10.1101/gad.1487307 · Cited by 406
Self-citationIdentification of Aneuploidy-Selective Antiproliferation Compounds
Tang, Y.-C., Williams, B. R., Siegel, J. J., & Amon, A. (2011) · Cell · doi:10.1016/j.cell.2011.01.017 · Cited by 328
The combined status of ATM and p53 link tumor development with therapeutic response
Jiang, H., Reinhardt, H. C., Bartkova, J., Tommiska, J., Blomqvist, C., Nevanlinna, H., Bartek, J., Yaffe, M. B., & Hemann, M. T. (2009) · Genes & Development · doi:10.1101/gad.1815309 · Cited by 304
Metadata
- Authors
- Mukhopadhyay, U. K., Senderowicz, A. M., & Ferbeyre, G.
- Venue
- Cancer Research
- Published
- 2005-04-01
- Volume
- 65
- Issue
- 7
- Pages
- 2872-2881
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2115751699
- Cited by
- 47
- References
- 5
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RNA Silencing of Checkpoint Regulators Sensitizes p53 -Defective Prostate Cancer Cells to Chemotherapy while Sparing Normal Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-2502
- The paper
- Mukhopadhyay, U. K., Senderowicz, A. M., & Ferbeyre, G. (2005). RNA Silencing of Checkpoint Regulators Sensitizes p53 -Defective Prostate Cancer Cells to Chemotherapy while Sparing Normal Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-2502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.